BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 09, 2009
 |  BioCentury  |  Strategy

Folotyn Follows Price Signals

Even though the price Allos Therapeutics Inc. has set for Folotyn pralatrexate exceeds analyst estimates by 20-120%, the company does not expect pushback from payers. Its reason is that Folotyn has proven efficacy in an Orphan cancer for which expensive agents used off-label are already being reimbursed.

When Folotyn received accelerated approval from FDA in September, the small molecule dihydrofolate reductase (DHFR) inhibitor became the first agent ever approved for refractory peripheral T cell lymphoma. PTCL is a subset of non-Hodgkin's lymphoma with an overall incidence of 19,900 patients in the U.S. An estimated 9,850 are relapsed/refractory patients being treated or referred for treatment or a clinical trial.

Because Allos had declined to provide any pricing benchmarks for Folotyn at the time of approval, analyst estimates ranged widely, from $54,000 up to $100,000 per patient per year.

Last month, the company...

Read the full 703 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >